RT Journal Article
SR Electronic
T1 Peripheral monocyte transcriptomics associated with immune checkpoint blockade outcomes in metastatic melanoma
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.01.25.24301653
DO 10.1101/2024.01.25.24301653
A1 Cooper, Rosalin A
A1 Taylor, Chelsea A
A1 Watson, Robert A
A1 Tong, Orion
A1 Nassiri, Isar
A1 Sharma, Piyush Kumar
A1 Little, Martin
A1 Ye, Weiyu
A1 Koturan, Surya
A1 Danielli, Sara
A1 Middleton, Mark
A1 Fairfax, Benjamin P
YR 2024
UL http://medrxiv.org/content/early/2024/01/25/2024.01.25.24301653.abstract
AB Clinical responses to immune checkpoint blockade (ICB) for metastatic melanoma (MM) are variable, with patients frequently developing immune related adverse events (irAEs). The role played by myeloid populations in modulating responses to ICB remains poorly defined. We explored the effect of MM and the response to ICB across a cohort of patients with MM (n=116) and healthy donors (n=45) using bulk and single cell RNA-seq, and flow cytometry. Monocytes from patients with MM exhibit highly dysregulated baseline transcriptional profiles, whilst ICB treatment elicits induction of interferon signaling, MHC class II antigen presentation and CXCR3 ligand expression. Although both combination (cICB - anti-PD-1 and anti-CTLA) and single-agent (sICB - anti-PD1) ICB therapy modulates a shared set of genes, cICB displays a markedly greater magnitude of transcriptional effect. Notably, we find increased baseline monocyte counts correlate with a monocyte proliferation signature and risk of early death, whilst a gene-signature corresponding to a subset of platelet-binding classical monocytes conversely associates with improved outcome. This work demonstrates a central role for monocytes in the modulation of treatment response to ICB, providing insights into inter-individual variation in immune responses to ICB and further highlighting the multifarious immunological consequences of ICB treatment.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was funded by a Wellcome Trust Intermediate Clinical fellowship held by BPF (no. 201488/Z/16/Z). RAC was funded by CRUK Clinical Research Training Fellowship (S_3578). CAT was funded by the Engineering and Physical Sciences Research Council and Balliol Jowett Society (no. D4T00070). RAW was funded by a Wellcome Trust Doctoral Training Fellowship (no. BST00070). OT was funded by the Clarendon Fund and Oxford Australia Fellowship and St Edmunds Hall. WY was supported by an NIHR ACF and a CRUK Predoctoral Fellowship (ref. RCCTI100019). MM and BPF are supported by the NIHR Oxford Biomedical Research Centre.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All patients provided prior written informed consent for their samples to be donated to the Oxford Radcliffe Biobank (Approved by South Central Oxford C Research Ethics Committee 12th April 2019, Reference 19/SC/0173 with internal Oxford Centre for Histopathology Research ethical approval, 16/A019, 18/A064) to be used for research. Control samples were obtained from the Oxford biobank (Integrated Research Application System Project number: 329964, South Central Oxford C. Research Ethics Committee approval, ID 23/SC/0411) after informed written consent was obtained under approval for the 'Genetic diversity and gene expression in white blood cells' project which was given by Oxford B Research Ethics Committee, reference 06/Q1605/55. I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in this study are available upon reasonable request to the authors and will be disseminated through online repositories at the time of publication.